

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Yong-Li Ruan et al.

Application No.: 10/003,405

Filing Date: December 6, 2001

Title: MODIFICATION OF SUCROSE SYNTHASE GENE EXPRESSION IN PLANT TISSUE AND USES  
THEREFOR

Group Art Unit: 1638

Examiner: RUSSELL KALLIS

Confirmation No.: 5391

THIRD  
INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTERCommissioner for Patents  
P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Enclosed is a THIRD Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- No additional fee for submission of an IDS is required.
- The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- Charge \_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of \$ 180.00 is enclosed for the fee due.
- Charge \_\_\_\_\_ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER &amp; MATHIS, L.L.P.

By



Eric H. Weisblatt

Registration No. 30,505

Date: April 29, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Yong-Li Ruan et al.

Application No.: 10/003,405

Filed: December 6, 2001

For: MODIFICATION OF SUCROSE  
SYNTHASE GENE EXPRESSION IN  
PLANT TISSUE AND USES  
THEREFOR



) Group Art Unit: 1638

) Examiner: RUSSELL KALLIS

) Confirmation No.: 5391

THIRD INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

A fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:

  
Eric H. Weisblatt  
Registration No. 30,505

Date April 29, 2005

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

THIRD  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)


Sheet 1 of 1

Sheet 1 of 1

<i>Complete if Known</i>	
<b>Application Number</b>	10/003,405
<b>Filing Date</b>	December 6, 2001
<b>First Named Inventor</b>	Yong-Li Ruan et al.
<b>Examiner Name</b>	RUSSELL KALLIS
<b>Attorney Docket Number</b>	021565-110

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
01PE				



## FOREIGN PATENT DOCUMENTS

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	<a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=349737">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=349737</a> , 27/04/2005
	<a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=19099">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=19099</a> , 27/04/2005
	<a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=20072">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=20072</a> , 27/04/2005
	<a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=21341">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=21341</a> , 27/04/2005
	<a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=160571">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=160571</a> , 27/04/2005
	<a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=511945">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=511945</a> , 27/04/2005
	<a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=1700046">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=1700046</a> , 27/04/2005
	<a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=1406569">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=1406569</a> , 27/04/2005
	<a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=100010">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=100010</a> , 27/04/2005
	<a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=220037">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=220037</a> , 27/04/2005

Examiner /Russell Kallis/ Date Considered 09/30/2008

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.